Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics

European Journal of Pharmacology

Volumn 545, Issue 1, 2006, Pages 39-50

  Butterfield, D Allan ^a,b   Perluigi, Marzia ^a,c   Sultana, Rukhsana ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Hippocampus; Inferior parietal lobule; Oxidative stress; Protein oxidation; Redox proteomics

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN[25-35]; AMYLOID PROTEIN; CARBONYL DERIVATIVE; LIPID; STRUCTURAL PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN REGION; BRAIN TISSUE; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; DATA BASE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; EXCITOTOXICITY; HUMAN; LONG TERM POTENTIATION; MASS SPECTROMETRY; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PH; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SYNAPSE; TWO DIMENSIONAL ELECTROPHORESIS;

ACTINS; ALZHEIMER DISEASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; HYDROGEN-ION CONCENTRATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LONG-TERM POTENTIATION; MASS SPECTROMETRY; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURITES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOME; PROTEOMICS; SYNAPSES; TAU PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 33747036919     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.026     Document Type: Review

References (129)

1. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., and Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103 (2001) 373-383
2. Aksenova M., Butterfield D.A., Zhang S.X., Underwood M., and Geddes J.W. Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J. Neurotrauma 19 (2002) 491-502
3. Anderson N.L., Matheson A.D., and Steiner S. Proteomics: applications in basic and applied biology. Curr. Opin. Biotechnol. 11 (2000) 408-412
4. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
5. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C., Perry R., Watson Jr. B., Bassett S.S., McInnis M.G., Albert M.S., Hyman B.T., and Tanzi R.E. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19 (1998) 357-360
6. Blass J.P., Gibson G.E., and Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J. Alzheimer's Dis. 4 (2002) 225-232
7. Boyd-Kimball D., Mohmmad-Abdul H., Reed T., Sultana R., and Butterfield D.A. Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Chem. Res. Toxicol. 17 (2004) 1743-1749
8. Bruce-Keller A.J., Li Y.J., Lovell M.A., Kraemer P.J., Gary D.S., Brown R.R., Markesbery W.R., and Mattson M.P. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J. Neuropathol. Exp. Neurol. 57 (1998) 257-267
9. Bubber P., Haroutunian V., Fisch G., Blass J.P., and Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57 (2005) 695-703
10. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36 (2002) 1307-1313
11. Butterfield D.A. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 1000 (2004) 1-7
12. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32 (2002) 1050-1060
13. Butterfield D.A., and Pocernich C.B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 17 (2003) 641-652
14. Butterfield D.A., and Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. vol. 2 (1997) 161-191
15. Butterfield D.A., Hensley K., Cole P., Subramaniam R., Aksenov M., Aksenova M., Bummer P.M., Haley B.E., and Carney J.M. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J. Neurochem. 68 (1997) 2451-2457
16. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
17. Butterfield D.A., Boyd-Kimball D., and Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86 (2003) 1313-1327
18. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33 (2002) 562-571
19. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82 (2002) 1524-1532
20. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., and Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85 (2003) 1394-1401
21. Castegna A., Lauderback C.M., Mohmmad-Abdul H., and Butterfield D.A. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. 1004 (2004) 193-197
22. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., and Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279 (2004) 13256-13264
23. Coleman P.D., and Flood D.G. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol. Aging 8 (1987) 521-545
24. Cross C.E., Halliwell B., Borish E.T., Pryor W.A., Ames B.N., Saul R.L., McCord J.M., and Harman D. Oxygen radicals and human disease. Ann. Intern. Med. 107 (1987) 526-545
25. Cruts M., van Duijn C.M., Backhovens H., Van den Broeck M., Wehnert A., Serneels S., Sherrington R., Hutton M., Hardy J., St George-Hyslop P.H., Hofman A., and Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum. Mol. Genet. 7 (1998) 43-51
26. Csordas G., and Hajnoczky G. Plasticity of mitochondrial calcium signaling. J. Biol. Chem. 278 (2003) 42273-42282
27. Dahiyat M., Cumming A., Harrington C., Wischik C., Xuereb J., Corrigan F., Breen G., Shaw D., and St Clair D. Association between Alzheimer's disease and the NOS3 gene. Ann. Neurol. 46 (1999) 664-667
28. Dalle-Donne I., Scaloni A., Giustarini D., Cavarra E., Tell G., Lungarella G., Colombo R., Rossi R., and Milzani A. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom. Rev. 24 (2005) 55-99
29. Dalle-Donne, I., Scaloni, A., Butterfield, D.A., 2006. Redox proteomics. New York: Wiley.
30. Davies K.J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83 (2001) 301-310
31. Davies M.J., Fu S., Wang H., and Dean R.T. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic. Biol. Med. 27 (1999) 1151-1163
32. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
33. Esser C., Alberti S., and Hohfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim. Biophys. Acta 1695 (2004) 171-188
34. Gabbita S.P., Lovell M.A., and Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71 (1998) 2034-2040
35. Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y., Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E., Zheng H., Van Der Ploeg L.H., Ruffolo S.C., Thornberry N.A., Xanthoudakis S., Zamboni R.J., Roy S., and Nicholson D.W. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97 (1999) 395-406
36. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
37. Good P.F., Werner P., Hsu A., Olanow C.W., and Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149 (1996) 21-28
38. Grune T., Reinheckel T., and Davies K.J. Degradation of oxidized proteins in mammalian cells. FASEB J. 11 (1997) 526-534
39. Halliwell B. Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann. N. Y. Acad. Sci. 962 (2002) 182-194
40. Hamajima N., Matsuda K., Sakata S., Tamaki N., Sasaki M., and Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 180 (1996) 157-163
41. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
42. Healy D.G., Abou-Sleiman P.M., and Wood N.W. Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res. 318 (2004) 189-194
43. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 (1995) 2146-2156
44. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., and Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21 (2001) 3017-3023
45. Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy vol. 4 (2005) 247-256
46. Hoogland C., Sanchez J.C., Tonella L., Binz P.A., Bairoch A., Hochstrasser D.F., and Appel R.D. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res. 28 (2000) 286-288
47. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry 36 Suppl. 1 (2003) S62-S67
48. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv. Exp. Med. Biol. 541 (2004) 135-152
49. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 45 (2004) 583-595
50. Hyun D.H., Lee M.H., Halliwell B., and Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J. Neurochem. 83 (2002) 360-370
51. Hyun D.H., Gray D.A., Halliwell B., and Jenner P. Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. J. Neurochem. 90 (2004) 422-430
52. Ivins K.J., Thornton P.L., Rohn T.T., and Cotman C.W. Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol. Dis. 6 (1999) 440-449
53. Jonas E.A., Hoit D., Hickman J.A., Brandt T.A., Polster B.M., Fannjiang Y., McCarthy E., Montanez M.K., Hardwick J.M., and Kaczmarek L.K. Modulation of synaptic transmission by the BCL-2 family protein BCL-xL. J. Neurosci. 23 (2003) 8423-8431
54. Junge W., Lill H., and Engelbrecht S. ATP synthase: an electrochemical transducer with rotatory mechanics. Trends Biochem. Sci. 22 (1997) 420-423
55. Kaech S., Brinkhaus H., and Matus A. Volatile anesthetics block actin-based motility in dendritic spines. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10433-10437
56. Kato Y., Hamajima N., Inagaki H., Okamura N., Koji T., Sasaki M., and Nonaka M. Post-meiotic expression of the mouse dihydropyrimidinase-related protein 3 (DRP-3) gene during spermiogenesis. Mol. Reprod. Dev. 51 (1998) 105-111
57. Katzman R., and Saitoh T. Advances in Alzheimer's disease. FASEB J. 5 (1991) 278-286
58. Keller J.N., Hanni K.B., and Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75 (2000) 436-439
59. Lafon-Cazal M., Viennois G., Kuhn R., Malitschek B., Pin J.P., Shigemoto R., and Bockaert J. mGluR7-like receptor and GABA(B) receptor activation enhance neurotoxic effects of N-methyl-d-aspartate in cultured mouse striatal GABAergic neurones. Neuropharmacology 38 (1999) 1631-1640
60. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., and Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78 (2001) 413-416
61. Le Prince G., Delaere P., Fages C., Lefrancois T., Touret M., Salanon M., and Tardy M. Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem. Res. 20 (1995) 859-862
62. Levy-Lahad E., Lahad A., Wijsman E.M., Bird T.D., and Schellenberg G.D. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann. Neurol. 38 (1995) 678-680
63. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
64. Lorenzo H.K., Susin S.A., Penninger J., and Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 6 (1999) 516-524
65. Lovell M.A., and Markesbery W.R. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58 (2001) 392-396
66. Lovell M.A., Xie C., and Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 22 (2001) 187-194
67. Lovell M.A., Xiong S., Markesbery W.R., and Lynn B.C. Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem. Res. 30 (2005) 113-122
68. Lu Plj., Wulf G., Zhou X.Z., Davies P., and Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399 (1999) 784-788
69. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
70. Mattson M.P., and Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2 (2002) 215-231
71. McClellan A.J., Tam S., Kaganovich D., and Frydman J. Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol. 7 (2005) 736-741
72. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
73. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
74. Mecocci P., MacGarvey U., and Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36 (1994) 747-751
75. Meier-Ruge W., Iwangoff P., and Reichlmeier K. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch. Gerontol. Geriatr. 3 (1984) 161-165
76. Mohmmad Abdul H., and Butterfield D.A. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochim. Biophys. Acta 1741 (2005) 140-148
77. Molina J.A., de Bustos F., Jimenez-Jimenez F.J., Benito-Leon J., Gasalla T., Orti-Pareja M., Vela L., Bermejo F., Martin M.A., Campos Y., and Arenas J. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Neurology 48 (1997) 636-638
78. Nakamura K., Hori T., Sato N., Sugie K., Kawakami T., and Yodoi J. Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene 8 (1993) 3133-3139
79. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., and Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19 (1999) 1959-1964
80. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
81. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250 (1975) 4007-4021
82. Paumi C.M., Ledford B.G., Smitherman P.K., Townsend A.J., and Morrow C.S. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 276 (2001) 7952-7956
83. Petropoulos I., Conconi M., Wang X., Hoenel B., Bregegere F., Milner Y., and Friguet B. Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 55 (2000) B220-B227
84. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., and Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23 (1998) 81-88
85. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2 (2002) 3-10
86. Ramakrishnan P., Dickson D.W., and Davies P. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiol. Dis. 14 (2003) 251-264
87. Rego A.C., and Oliveira C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 28 (2003) 1563-1574
88. Rivett A.J. Regulation of intracellular protein turnover: covalent modification as a mechanism of marking proteins for degradation. Curr. Top. Cell. Regul. 28 (1986) 291-337
89. Roix J., and Misteli T. Genomes, proteomes, and dynamic networks in the cell nucleus. Histochem. Cell Biol. 118 (2002) 105-116
90. Saido T.C. Overview-Aβ metabolism: from Alzheimer research to brain aging control. In: Saido T.C. (Ed). Aβ Metabolism and Alzheimer's Disease (2003), Landes Bioscience, Georgetown, TX 1-16
91. Salmon D.P., Thomas R.G., Pay M.M., Booth A., Hofstetter C.R., Thal L.J., and Katzman R. Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology 59 (2002) 1022-1028
92. Santoni V., Molloy M., and Rabilloud T. Membrane proteins and proteomics: un amour impossible?. Electrophoresis 21 (2000) 1054-1070
93. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., and Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68 (1997) 2092-2097
94. Schagger H., and Ohm T.G. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur. J. Biochem. 227 (1995) 916-921
95. Sergeant N., Wattez A., Galvan-valencia M., Ghestem A., David J.P., Lemoine J., Sautiere P.E., Dachary J., Mazat J.P., Michalski J.C., Velours J., Mena-Lopez R., and Delacourte A. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117 (2003) 293-303
96. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab. Rev. 32 (2000) 307-326
97. Shen J., Yang X., Dong A., Petters R.M., Peng Y.W., Wong F., and Campochiaro P.A. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J. Cell Physiol. 203 (2005) 457-464
98. Sitte N., Huber M., Grune T., Ladhoff A., Doecke W.D., Von Zglinicki T., and Davies K.J. Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. FASEB J. 14 (2000) 1490-1498
99. Slooter A.J., Cruts M., Kalmijn S., Hofman A., Breteler M.M., Van Broeckhoven C., and van Duijn C.M. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch. Neurol. 55 (1998) 964-968
100. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., and Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10540-10543
101. Smith M.A., Richey P.L., Taneda S., Kutty R.K., Sayre L.M., Monnier V.M., and Perry G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 738 (1994) 447-454
102. Smith M.A., Sayre L.M., Monnier V.M., and Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18 (1995) 172-176
103. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
104. Smolka M.B., Zhou H., Purkayastha S., and Aebersold R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal. Biochem. 297 (2001) 25-31
105. Staal F.J., Anderson M.T., Staal G.E., Herzenberg L.A., and Gitler C. Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3619-3622
106. Stadtman E.R., and Levine R.L. Protein oxidation. Ann. N. Y. Acad. Sci. 899 (2000) 191-208
107. Stadtman E.R., Oliver C.N., Levine R.L., Fucci L., and Rivett A.J. Implication of protein oxidation in protein turnover, aging, and oxygen toxicity. Basic Life Sci. 49 (1988) 331-339
108. Starke-Reed P.E., and Oliver C.N. Protein oxidation and proteolysis during aging and oxidative stress. Arch. Biochem. Biophys. 275 (1989) 559-567
109. Stenbeck G. Soluble NSF-attachment proteins. Int. J. Biochem. Cell Biol. 30 (1998) 573-577
110. Stevens Jr. S.M., Kem W.R., and Prokai L. Investigation of cytolysin variants by peptide mapping: enhanced protein characterization using complementary ionization and mass spectrometric techniques. Rapid Commun. Mass Spectrom. 16 (2002) 2094-2101
111. Sultana R., and Butterfield D.A. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res. 29 (2004) 2215-2220
112. Sultana R., Boyd-Kimball D.A., Poon H.F., Cai j., Pierce W.M., Klein J.B., Markesbery W.R., and Butterfield D.A. Oxidative modification and down-regulation of Pin 1 Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging. 27 (2006) 918-925
113. Sultana R., Poon H.F., Cai j., Pierce W.M., Merchant M., Klein J.B., Markesbery W.R., and Butterfield D.A. Identification of nitrated proteins in Alzheimer's disease brain using redox proteomics approach. Neurobiol. Dis. 22 (2006) 76-87
114. Sultana, R., Boyd-Kimball, D., Poon, H.F., Cai, j, Pierce, W.M., Klein, J.B., Markesbery, W.R., Butterfield, D.A., in press. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging.
115. Summers W.K. Alzheimer's disease, oxidative injury, and cytokines. J. Alzheimer's Dis. 6 (2004) 651-657 (discussion 673-681)
116. Sun M.K., and Alkon D.L. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol. Sci. 23 (2002) 83-89
117. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N., Prevost M.C., Alzari P.M., and Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189 (1999) 381-394
118. Szweda P.A., Friguet B., and Szweda L.I. Proteolysis, free radicals, and aging. Free Radic. Biol. Med. 33 (2002) 29-36
119. Tilleman K., Stevens I., Spittaels K., Haute C.V., Clerens S., Van Den Bergh G., Geerts H., Van Leuven F., Vandesande F., and Moens L. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics 2 (2002) 94-104
120. Tuppo E.E., and Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37 (2005) 289-305
121. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., and Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4766-4770
122. Wagner Y., Sickmann A., Meyer H.E., and Daum G. Multidimensional nano-HPLC for analysis of protein complexes. J. Am. Soc. Mass Spectrom. 14 (2003) 1003-1011
123. Wang J., Xiong S., Xie C., Markesbery W.R., and Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 93 (2005) 953-962
124. Watson G.S., and Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 490 (2004) 97-113
125. Weeber E.J., Levy M., Sampson M.J., Anflous K., Armstrong D.L., Brown S.E., Sweatt J.D., and Craigen W.J. The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J. Biol. Chem. 277 (2002) 18891-18897
126. Wojcik C. Regulation of apoptosis by the ubiquitin and proteasome pathway. J. Cell. Mol. Med. 6 (2002) 25-48
127. Yatin S.M., Varadarajan S., and Butterfield D.A. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimer's Dis. 2 (2000) 123-131
128. Yoo B.C., Fountoulakis M., Cairns N., and Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22 (2001) 172-179
129. Zaid H., Abu-Hamad S., Israelson A., Nathan I., and Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ. 12 (2005) 751-760